decreased intensity of IPH levels measured by MRI
Image quality will be assessed from 1 to 5 (grade 1, low Signal-to-Noise Ratio (SNR) limits use, arterial wall and vessel margins are unidentifiable; grade 2, marginal SNR, arterial wall is visible, but the substructure, lumen, and outer boundaries are indistinct; grade 3, marginal SNR, wall structures are identifiable, but lumen and outer boundaries are partially obscured; grade 4, high SNR with minimal artifacts, vessel wall, lumen, and adventitial margins are well defined; and grade 5, high SNR without artifacts, wall architecture depicted in detail, lumen and adventitial boundary are clearly defined) . If the quality of the image is sufficient (≥ 3), IPH levels will be semi-quantified on a scale from 0 to 3 (0: No IPH, 1: light IPH, 2 moderate IPH, strong IPH). Images will be assessed blindly and independently by clinical experts of carotid plaque imaging.
decreased intensity of IPH levels measured by MRI
Image quality will be assessed from 1 to 5 (grade 1, low Signal-to-Noise Ratio (SNR) limits use, arterial wall and vessel margins are unidentifiable; grade 2, marginal SNR, arterial wall is visible, but the substructure, lumen, and outer boundaries are indistinct; grade 3, marginal SNR, wall structures are identifiable, but lumen and outer boundaries are partially obscured; grade 4, high SNR with minimal artifacts, vessel wall, lumen, and adventitial margins are well defined; and grade 5, high SNR without artifacts, wall architecture depicted in detail, lumen and adventitial boundary are clearly defined) . If the quality of the image is sufficient (≥ 3), IPH levels will be semi-quantified on a scale from 0 to 3 (0: No IPH, 1: light IPH, 2 moderate IPH, strong IPH). Images will be assessed blindly and independently by clinical experts of carotid plaque imaging.
Evaluation of intermediate monocyte phenotype (cluster of differentiation 14 (CD14)++ /cluster of differentiation 16 (CD16)+)
monocytes will be extracted from blood sample, marked with specific antibodies (anti CD14/16) and intermediate phenotypes (in %) will be measured by flow cytometry
Evaluation of intermediate monocyte phenotype (cluster of differentiation 14 (CD14)++ /cluster of differentiation 16 (CD16)+)
monocytes will be extracted from blood sample, marked with specific antibodies (anti CD14/16) and intermediate phenotypes (in %) will be measured by flow cytometry
Evaluation of classical monocyte phenotype (cluster of differentiation 14 (CD14)++ /cluster of differentiation 16 (CD16)-)
monocytes will be extracted from blood sample, marked with specific antibodies (anti CD14/16) and classical phenotypes (in %) will be measured by flow cytometry
Evaluation of classical monocyte phenotype (cluster of differentiation 14 (CD14)++ /cluster of differentiation 16 (CD16)-)
monocytes will be extracted from blood sample, marked with specific antibodies (anti CD14/16) and classical phenotypes (in %) will be measured by flow cytometry
Evaluation of non-classical monocyte phenotype (cluster of differentiation 14 (CD14)+ /cluster of differentiation 16 (CD16)++)
monocytes will be extracted from blood sample, marked with specific antibodies (anti CD14/16) and non-classical phenotypes (in %) will be measured by flow cytometry
Evaluation of non-classical monocyte phenotype (cluster of differentiation 14 (CD14)+ /cluster of differentiation 16 (CD16)++)
monocytes will be extracted from blood sample, marked with specific antibodies (anti CD14/16) and non-classical phenotypes (in %) will be measured by flow cytometry
Assessment of red blood cell aggregation
Red blood cell aggregation (in %)will be measured by ektacytometry
Assessment of red blood cell aggregation
Red blood cell aggregation (in %) will be measured by ektacytometry
in vitro clotting formation time
In vitro clotting formation time (in minutes) will be measured on whole blood by rotational thromboelastometry
in vitro clotting formation time
In vitro clotting formation time (in minutes) will be measured on whole blood by rotational thromboelastometry
Measurement of in vitro clot lysis index
In vitro clot lysis index (in millimeter) will be measured on whole blood by rotational thromboelastometry
Measurement of in vitro clot lysis index
In vitro clot lysis index (in millimeter) will be measured on whole blood by rotational thromboelastometry
Measurement of in vitro clot firmness
In vitro clot firmness (in millimeter) will be measured on whole blood by rotational thromboelastometry
Measurement of in vitro clot firmness
In vitro clot firmness (in millimeter) will be measured on whole blood by rotational thromboelastometry
Assessment of plasma lipid oxidation
Plasma protein oxidation (advanced oxidation proteins products) measured by by spectrophotometry (in micromole/liter (µmol/L))
Assessment of plasma lipid oxidation
Plasma protein oxidation (advanced oxidation proteins products) measured by by spectrophotometry (in micromole/liter (µmol/L))
Assessment of plasma protein oxidation
Plasma protein oxidation (advanced oxidation proteins products) measured by by spectrophotometry (in micromole/liter (µmol/L))
Assessment of plasma protein oxidation
Plasma protein oxidation (advanced oxidation proteins products) measured by by spectrophotometry (in micromole/liter (µmol/L))
Assessment of plasma protein nitration
Plasma protein nitration (nitrotyrosine) measured by the enzyme-linked immunosorbent assay (ELISA) in micromole/liter (µmol/L).
Assessment of plasma protein nitration
Plasma protein nitration (nitrotyrosine) measured by the enzyme-linked immunosorbent assay (ELISA) in micromole/liter (µmol/L).
Assessment of plasma inflammatory markers
Plasma inflammatory markers will be measured by multiplex assay in micromole/liter (µmol/L).
Assessment of plasma inflammatory markers
Plasma inflammatory markers will be measured by multiplex assay in micromole/liter (µmol/L).
Assessment of plasma enzymes activity
Plasma antioxidant enzymes activity will be measured by enzymology (in micromole/liter/minute (µmol/L/min))
Assessment of plasma enzymes activity
Plasma antioxidant enzymes activity will be measured by enzymology (in micromole/liter/minute (µmol/L/min))
number of steps per day
the daily number of steps (in number of step per day) will be measured using a connected wrist activity tracker
number of steps per day
the daily number of steps (in number of step per day) will be measured using a connected wrist activity tracker
distance of the 6 minutes walking test
The distance at the 6 minutes walking test (in meters) will be evaluated on the 30meters flat round-trip
distance of the 6 minutes walking test
The distance at the 6 minutes walking test (in meters) will be evaluated on the 30meters flat round-trip
quadriceps maximal isometric strength
The quadriceps maximal isometric strength (in Newton) will be evaluated in sitting position using dynamometer
quadriceps maximal isometric strength
The quadriceps maximal isometric strength (in Newton) will be evaluated in sitting position using dynamometer
Determination of the level of physical activity
the level physical activity will be evaluated by the global physical activity questionnaire (in Metabolic Equivalent of Task/minutes per week (MET/min.week)).
Determination of the level of physical activity
the level physical activity will be evaluated by the global physical activity questionnaire (in Metabolic Equivalent of Task/minutes per week (MET/min.week)).
Determination of the sedentary time
Sedentary time will be evaluated by the sedentary behaviour questionnaire evaluating the total daily sitting and lying down time (in minute/day) during awaking time.
Determination of the sedentary time
Sedentary time will be evaluated by the sedentary behaviour questionnaire evaluating the total daily sitting and lying down time (in minute/day) during awaking time.
descriptive health state score
Health state score will be assessed using descriptive system of the EQ-5D-5L (five-level version of the EuroQol five-dimensional) questionnaire.
Health status is measured in terms of five dimensions (5D); mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The subjects self-rate their level of severity for each dimension using a five-level (EQ-5D-5L) scale (scored from 1 to 5, 1 indicating no problem and 5 indicating extreme problem).
The health rate score correspond to the addition of each dimension score and is from 5 to 25. The lower the score, the better the health state.
descriptive health state score
Health state score will be assessed using descriptive system of the EQ-5D-5L (five-level version of the EuroQol five-dimensional) questionnaire.
Health status is measured in terms of five dimensions (5D); mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The subjects self-rate their level of severity for each dimension using a five-level (EQ-5D-5L) scale (scored from 1 to 5, 1 indicating no problem and 5 indicating extreme problem).
The health rate score correspond to the addition of each dimension score and is from 5 to 25. The lower the score, the better the health state.
self-evaluated overall health status
Overall health status will be assessed using the evaluation part of the EQ-5D-5L (five-level version of the EuroQol five-dimensional) questionnaire.
The subject's self- evaluate their overall health status using the visual analogue scale (EQ-VAS).
The raw score is from 0 to 100. The higher the score, the better the perceived overall health status
self-evaluated overall health status
Overall health status will be assessed using the evaluation part of the EQ-5D-5L (five-level version of the EuroQol five-dimensional) questionnaire.
The subject's self- evaluate their overall health status using the visual analogue scale (EQ-VAS).
The raw score is from 0 to 100. The higher the score, the better the perceived overall health status
body mass index
Body mass index (in kilogram/metre² (kg/m²)) will be calculated with the measurement of body weight (in kilogram) and height (in meter)
body mass index
Body mass index (in kilogram/metre² (kg/m²)) will be calculated with the measurement of body weight (in kilogram) and height (in meter)
number of comorbidities
Number of comorbidities (Diabetes, hypertension, obesity and , poly-atheroma) will be determined
number of comorbidities
Number of comorbidities (Diabetes, hypertension, obesity and , poly-atheroma) will be determined